In our study, the subset of HCC patients with B7-H3high/CD8high may have the greatest benefit from B7-H3 inhibitor therapy as it may reactivate the antitumor response of CD8+ T cells and prolong the survival of patients. This evidence concerns the gene CD276 and hepatocellular carcinoma.